Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $53.00.

Several equities research analysts have recently weighed in on COLL shares. Truist Financial set a $58.00 target price on Collegium Pharmaceutical in a research report on Tuesday, February 10th. Weiss Ratings reissued a “buy (b-)” rating on shares of Collegium Pharmaceutical in a report on Monday, December 29th. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Barclays lowered their target price on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a report on Friday, January 9th. Finally, Needham & Company LLC cut their price target on shares of Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating on the stock in a research note on Thursday.

Insider Activity

In other news, EVP Scott Dreyer sold 17,600 shares of Collegium Pharmaceutical stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $48.17, for a total transaction of $847,792.00. Following the sale, the executive vice president owned 103,613 shares in the company, valued at approximately $4,991,038.21. The trade was a 14.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the completion of the sale, the director directly owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. This trade represents a 6.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

A number of large investors have recently bought and sold shares of the business. Group One Trading LLC purchased a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $28,000. Federated Hermes Inc. lifted its holdings in Collegium Pharmaceutical by 67.0% in the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 350 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth $61,000. CWM LLC grew its stake in shares of Collegium Pharmaceutical by 453.9% during the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 1,153 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 318 shares during the period.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $41.11 on Monday. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59. The company has a fifty day simple moving average of $46.50 and a 200-day simple moving average of $42.09. The stock has a market cap of $1.31 billion, a P/E ratio of 24.07 and a beta of 0.67. Collegium Pharmaceutical has a 12-month low of $23.23 and a 12-month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). The business had revenue of $205.45 million during the quarter, compared to analyst estimates of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The firm’s quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.77 earnings per share. Equities analysts expect that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.